title: Triple or dual therapy for HCV-1 naive patients? Optimizing selection tools.
authors.affiliation: Department of Infectious Diseases, University of Turin, Amedeo di Savoia Hospital, Turin, Italy. Electronic address: lucio.boglione@unito.it.
authors.forename: Lucio
authors.initials: L
authors.lastname: Boglione
authors.affiliation: Department of Infectious Diseases, University of Turin, Amedeo di Savoia Hospital, Turin, Italy.
authors.forename: Amedeo
authors.initials: A
authors.lastname: De Nicolò
authors.affiliation: Department of Infectious Diseases, University of Turin, Amedeo di Savoia Hospital, Turin, Italy.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Di Perri
authors.affiliation: Department of Infectious Diseases, University of Turin, Amedeo di Savoia Hospital, Turin, Italy.
authors.forename: Antonio
authors.initials: A
authors.lastname: D'Avolio
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage*; D005260:Female; D016174:Hepacivirus / Q000145:classification*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage*; D008297:Male; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D012254:Ribavirin / Q000008:administration & dosage*
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D011092:Polyethylene Glycols; D012254:Ribavirin